6 Tahrir Street, Dokki, Giza, Egypt.
Br J Ophthalmol. 2010 May;94(5):606-10. doi: 10.1136/bjo.2009.168013. Epub 2009 Dec 2.
AIM To evaluate the role of intravitreal Triamcinolone (TA) in the early management of Coats disease. METHODS Retrospective, interventional case series. RESULTS 15 consecutive cases with Coats disease were managed with 4 mg/0.1 ml intravitreal TA injection on presentation and were followed for a minimum of 1 year duration. Additional management strategies including drainage of subretinal fluid through an inferior sclerotomy, peripheral laser ablation and/or cryotherapy, cataract extraction and vitrectomy were performed. Improvement of visual acuity could be achieved compared with preoperative vision in all cases in this series, even when 40% needed cataract extraction with intraocular lens implantation. One patient needed antiglaucoma treatment to control raised intraocular pressure in this series. CONCLUSIONS Triamcinolone has a role in improving the rate of absorption of subretinal fluid and macular exudates in Coats disease. The major complication of 4 mg/0.1 ml intravitreal triamcinolone is cataract in 40% of cases in children.
目的 评估玻璃体内曲安奈德（TA）在 Coats 病早期治疗中的作用。
方法 回顾性、干预性病例系列研究。
结果 15 例连续的 Coats 病患者在就诊时接受了 4mg/0.1ml 玻璃体内 TA 注射治疗，并进行了至少 1 年的随访。其他治疗策略包括通过下巩膜切开术引流视网膜下液、周边激光光凝和/或冷冻治疗、白内障摘除和玻璃体切除术。与术前视力相比，本系列所有病例的视力均有所提高，即使有 40%的患者需要白内障摘除联合人工晶状体植入。本系列中有 1 例患者需要抗青光眼治疗来控制眼压升高。
结论 曲安奈德在提高 Coats 病患者视网膜下液和黄斑渗出物的吸收率方面具有一定作用。4mg/0.1ml 玻璃体内曲安奈德的主要并发症是 40%的儿童发生白内障。
